CN108047151A - 一种高收率钆布醇的制备方法 - Google Patents
一种高收率钆布醇的制备方法 Download PDFInfo
- Publication number
- CN108047151A CN108047151A CN201810004629.1A CN201810004629A CN108047151A CN 108047151 A CN108047151 A CN 108047151A CN 201810004629 A CN201810004629 A CN 201810004629A CN 108047151 A CN108047151 A CN 108047151A
- Authority
- CN
- China
- Prior art keywords
- gadobutrol
- preparation
- compound
- reaction
- gadolinium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZPDFIIGFYAHNSK-CTHHTMFSSA-K 2-[4,10-bis(carboxylatomethyl)-7-[(2r,3s)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+) Chemical compound [Gd+3].OC[C@@H](O)[C@@H](CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-CTHHTMFSSA-K 0.000 title claims abstract description 73
- 229960003411 gadobutrol Drugs 0.000 title claims abstract description 73
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 238000006243 chemical reaction Methods 0.000 claims abstract description 44
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 36
- ANOXEUSGZWSCQL-LOYHVIPDSA-N Cycleanine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3N(C)CCC=4C=C(OC)C(OC)=C(C3=4)O3)C=21)OC)OC)C1=CC=C3C=C1 ANOXEUSGZWSCQL-LOYHVIPDSA-N 0.000 claims abstract description 19
- PEVPVMCJEMVCAS-UHFFFAOYSA-N Cycleanine Natural products COc1cc2CCN(C)C3Cc4ccc(Oc5cccc6CCN(C)C(Cc7ccc(Oc(c1OC)c23)cc7)c56)cc4 PEVPVMCJEMVCAS-UHFFFAOYSA-N 0.000 claims abstract description 19
- ANOXEUSGZWSCQL-UHFFFAOYSA-N O-Methyl-isochondodendrin Natural products O1C(C2=3)=C(OC)C(OC)=CC=3CCN(C)C2CC(C=C2)=CC=C2OC(C=23)=C(OC)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 ANOXEUSGZWSCQL-UHFFFAOYSA-N 0.000 claims abstract description 19
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims abstract description 10
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940075613 gadolinium oxide Drugs 0.000 claims abstract description 4
- 229910001938 gadolinium oxide Inorganic materials 0.000 claims abstract description 4
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 22
- 229940125782 compound 2 Drugs 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 11
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 125000005587 carbonate group Chemical group 0.000 claims 1
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 abstract description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- -1 Prohance Chemical compound 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 230000004224 protection Effects 0.000 description 9
- 0 CC(C)(C)OC(CN(CCNCC(OC(C)(C)C)=O)CCN(CCNC=O)CC(OC(C)(C)C)=O)=* Chemical compound CC(C)(C)OC(CN(CCNCC(OC(C)(C)C)=O)CCN(CCNC=O)CC(OC(C)(C)C)=O)=* 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000002872 contrast media Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000003321 amplification Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000011167 hydrochloric acid Nutrition 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RVQPPNOBBOQDKA-UHFFFAOYSA-N CC(C)(C)OC(C[Br]=C)=O Chemical compound CC(C)(C)OC(C[Br]=C)=O RVQPPNOBBOQDKA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 2
- LXILGZQWYDINMA-UHFFFAOYSA-N O=CN1CCNCCNCCNCC1 Chemical compound O=CN1CCNCCNCCNCC1 LXILGZQWYDINMA-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GEKNCWQQNMEIMS-UHFFFAOYSA-N 4,4-dimethyl-3,5,8-trioxabicyclo[5.1.0]octane Chemical compound C1OC(C)(C)OCC2OC21 GEKNCWQQNMEIMS-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- OCDAWJYGVOLXGZ-VPVMAENOSA-K gadobenate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)C(C([O-])=O)COCC1=CC=CC=C1 OCDAWJYGVOLXGZ-VPVMAENOSA-K 0.000 description 1
- ZPDFIIGFYAHNSK-UHFFFAOYSA-K gadobutrol Chemical compound [Gd+3].OCC(O)C(CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-UHFFFAOYSA-K 0.000 description 1
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 description 1
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 1
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- DRKHJSDSSUXYTE-UHFFFAOYSA-L oxidanium;2-[bis[2-[carboxylatomethyl-[2-(2-methoxyethylamino)-2-oxoethyl]amino]ethyl]amino]acetate;gadolinium(3+) Chemical compound [OH3+].[Gd+3].COCCNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NCCOC DRKHJSDSSUXYTE-UHFFFAOYSA-L 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
% | C | H | N |
理论值 | 34.66 | 5.35 | 8.99 |
实测值 | 34.44 | 5.38 | 8.89 |
绝对误差 | 0.22 | 0.03 | 0.10 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810004629.1A CN108047151B (zh) | 2018-01-03 | 2018-01-03 | 一种高收率钆布醇的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810004629.1A CN108047151B (zh) | 2018-01-03 | 2018-01-03 | 一种高收率钆布醇的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108047151A true CN108047151A (zh) | 2018-05-18 |
CN108047151B CN108047151B (zh) | 2020-08-04 |
Family
ID=62126209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810004629.1A Active CN108047151B (zh) | 2018-01-03 | 2018-01-03 | 一种高收率钆布醇的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108047151B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109705104A (zh) * | 2019-01-28 | 2019-05-03 | 湖北天舒药业有限公司 | 钆系离子型造影剂中间体的制备方法及其应用 |
CN110835326A (zh) * | 2018-08-15 | 2020-02-25 | 正大天晴药业集团股份有限公司 | 大环螯合剂及其中间体的制备方法 |
CN112585121A (zh) * | 2018-08-23 | 2021-03-30 | St制药株式会社 | 制备钆布醇的方法 |
CN113087680A (zh) * | 2020-01-08 | 2021-07-09 | 威智医药有限公司 | Dota晶型及其制备方法 |
CN113105407A (zh) * | 2020-01-13 | 2021-07-13 | 北京北陆药业股份有限公司 | 一种钆布醇新型晶型及其制备方法 |
CN113387899A (zh) * | 2020-03-11 | 2021-09-14 | 株式会社Enzychem生命科学 | 制备钙立醇的方法 |
CN113527223A (zh) * | 2021-06-22 | 2021-10-22 | 安徽普利药业有限公司 | 一种钆布醇的精制方法 |
CN113549025A (zh) * | 2021-07-14 | 2021-10-26 | 江苏美迪克化学品有限公司 | 一种1,4,7,10-四氮杂环十二烷-1,4,7-三乙酸及其钠盐的制备方法 |
CN113880850A (zh) * | 2021-10-18 | 2022-01-04 | 苏州百灵威超精细材料有限公司 | 一种钆布醇中间体及制备方法和在制备钆布醇中的应用 |
CN114685390A (zh) * | 2022-04-01 | 2022-07-01 | 苏州美诺医药科技有限公司 | 一种钆布醇衍生物的制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0292689B1 (en) * | 1987-04-24 | 1996-07-31 | Bracco International B.V. | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs |
CN1259939A (zh) * | 1997-06-11 | 2000-07-12 | 伯拉考公司 | 大环螯合剂及其与顺磁性金属离子的螯合物的制备方法 |
CN1997671B (zh) * | 2004-06-14 | 2012-07-18 | 诺和诺德公司 | 通过硬金属离子亲和层析法的肽纯化 |
CN103260652A (zh) * | 2010-11-05 | 2013-08-21 | 伯拉考成像股份公司 | 显示不依赖于浓度的响应性的cest系统 |
CN103613557A (zh) * | 2013-10-18 | 2014-03-05 | 武汉利宝瑞医药科技有限公司 | 一种磁共振成像对比剂钆布醇的制备方法 |
-
2018
- 2018-01-03 CN CN201810004629.1A patent/CN108047151B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0292689B1 (en) * | 1987-04-24 | 1996-07-31 | Bracco International B.V. | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs |
CN1259939A (zh) * | 1997-06-11 | 2000-07-12 | 伯拉考公司 | 大环螯合剂及其与顺磁性金属离子的螯合物的制备方法 |
CN1997671B (zh) * | 2004-06-14 | 2012-07-18 | 诺和诺德公司 | 通过硬金属离子亲和层析法的肽纯化 |
CN103260652A (zh) * | 2010-11-05 | 2013-08-21 | 伯拉考成像股份公司 | 显示不依赖于浓度的响应性的cest系统 |
CN103613557A (zh) * | 2013-10-18 | 2014-03-05 | 武汉利宝瑞医药科技有限公司 | 一种磁共振成像对比剂钆布醇的制备方法 |
Non-Patent Citations (1)
Title |
---|
J. PLATZEK, ET AL: "Synthesis and Structure of a New Macrocyclic Polyhydroxylated Gadolinium Chelate Used as a Contrast Agent for Magnetic Resonance Imaging", 《INORG. CHEM.》 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110835326A (zh) * | 2018-08-15 | 2020-02-25 | 正大天晴药业集团股份有限公司 | 大环螯合剂及其中间体的制备方法 |
CN110835326B (zh) * | 2018-08-15 | 2023-04-14 | 正大天晴药业集团股份有限公司 | 大环螯合剂及其中间体的制备方法 |
CN112585121A (zh) * | 2018-08-23 | 2021-03-30 | St制药株式会社 | 制备钆布醇的方法 |
CN112585121B (zh) * | 2018-08-23 | 2023-11-21 | St制药株式会社 | 制备钆布醇的方法 |
JP7240397B2 (ja) | 2019-01-28 | 2023-03-15 | フーベイ ティアンシュ ファーマシューティカル カンパニー リミテッド | ガドリニウム系イオン性造影剤の中間体の調製方法及びその応用 |
WO2020154892A1 (zh) * | 2019-01-28 | 2020-08-06 | 湖北天舒药业有限公司 | 钆系离子型造影剂中间体的制备方法及其应用 |
CN109705104A (zh) * | 2019-01-28 | 2019-05-03 | 湖北天舒药业有限公司 | 钆系离子型造影剂中间体的制备方法及其应用 |
JP2021528361A (ja) * | 2019-01-28 | 2021-10-21 | フーベイ ティアンシュ ファーマシューティカル カンパニー リミテッドHubei Tianshu Pharmaceutical Co., Ltd | ガドリニウム系イオン性造影剤の中間体の調製方法及びその応用 |
CN113087680A (zh) * | 2020-01-08 | 2021-07-09 | 威智医药有限公司 | Dota晶型及其制备方法 |
CN113105407A (zh) * | 2020-01-13 | 2021-07-13 | 北京北陆药业股份有限公司 | 一种钆布醇新型晶型及其制备方法 |
CN113387899A (zh) * | 2020-03-11 | 2021-09-14 | 株式会社Enzychem生命科学 | 制备钙立醇的方法 |
CN113527223A (zh) * | 2021-06-22 | 2021-10-22 | 安徽普利药业有限公司 | 一种钆布醇的精制方法 |
CN113549025A (zh) * | 2021-07-14 | 2021-10-26 | 江苏美迪克化学品有限公司 | 一种1,4,7,10-四氮杂环十二烷-1,4,7-三乙酸及其钠盐的制备方法 |
CN113880850A (zh) * | 2021-10-18 | 2022-01-04 | 苏州百灵威超精细材料有限公司 | 一种钆布醇中间体及制备方法和在制备钆布醇中的应用 |
CN114685390A (zh) * | 2022-04-01 | 2022-07-01 | 苏州美诺医药科技有限公司 | 一种钆布醇衍生物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108047151B (zh) | 2020-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108047151A (zh) | 一种高收率钆布醇的制备方法 | |
CN103613557B (zh) | 一种磁共振成像对比剂钆布醇的制备方法 | |
CN102399199A (zh) | 一种磁共振成像造影剂的制备方法 | |
CN109761924A (zh) | 一种改进的缬沙坦反应混合液的后处理方法 | |
AU2011260310A1 (en) | Gadobutrol preparation in a one-pot process by means of DMF acetal and N-methylimidazole | |
CN108299322B (zh) | 一种制备钆布醇的方法 | |
CN107001294A (zh) | 一种用于制备钆布醇的方法 | |
JP2021183615A (ja) | Dota合成 | |
Gansow et al. | Synthesis and characterization of some bifunctional 2B: 2: 1 cryptands | |
CA2431976C (en) | Lithium complexes of n-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, their production and use | |
CN110240586A (zh) | 2,3-二氢-1H-苯并[f]色满-2-胺衍生物的制备方法 | |
IE59396B1 (en) | Process for the preparation of 2-alkoxy-n-(1-azabicyclo(2.2.2)octan-3-yl)amino-benzamides | |
CN105646446A (zh) | 一种纯化阿格列汀的方法 | |
CN105859747A (zh) | 一种适于工业化生产的盐酸头孢吡肟的制备方法 | |
CN114853689A (zh) | 一种高纯布醇锂络合物的制备方法 | |
JPS63295561A (ja) | 2−キノロン誘導体 | |
CN113272284B (zh) | 制备考布曲钙的方法 | |
JP2018104312A (ja) | イミダゾピロロキノリン塩及びその製造方法、並びに、医薬品、化粧品及び食品 | |
EP3875453A1 (en) | Method for manufacturing calcobutrol | |
CN102603550B (zh) | 一种中间体bopta的制备方法 | |
CN101684100B (zh) | 得拉唑沙或其可药用盐的制备方法 | |
CN101633639B (zh) | 一种高纯度的氟罗沙星化合物 | |
JP2011168507A (ja) | 複素環置換芳香族化合物、分子検出剤、分子検出方法、及び分子捕捉方法 | |
CN100506811C (zh) | (2s,3s)-3-[[(1s)-1-异丁氧基甲基-3-甲基丁基]氨基甲酰基]环氧乙烷-2-甲酸盐 | |
RU2779668C1 (ru) | Способ получения калькобутрола |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Lai Yingjie Inventor after: Liang Long Inventor after: Long Xiangtian Inventor after: Zhou Lei Inventor after: Bai Libin Inventor after: Cao Benwen Inventor after: Tan Junrong Inventor after: Xie Dexun Inventor before: Long Xiangtian Inventor before: Zhou Lei Inventor before: Lai Yingjie Inventor before: Bai Libin Inventor before: Cao Benwen Inventor before: Tan Junrong Inventor before: Liang Long Inventor before: Xie Dexun |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for the preparation of gadolinium butol with high yield Effective date of registration: 20200909 Granted publication date: 20200804 Pledgee: Guangzhou Caold financing Company limited by guarantee Pledgor: CHEN-STONE(GUANGZHOU) Co.,Ltd. Registration number: Y2020440000258 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220315 Granted publication date: 20200804 Pledgee: Guangzhou Caold financing Company limited by guarantee Pledgor: CHEN-STONE(GUANGZHOU) Co.,Ltd. Registration number: Y2020440000258 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Preparation Method of Gadolinium Butanol with High Yield Effective date of registration: 20221031 Granted publication date: 20200804 Pledgee: Guangzhou Caold financing Company limited by guarantee Pledgor: CHEN-STONE(GUANGZHOU) Co.,Ltd. Registration number: Y2022440000292 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231201 Granted publication date: 20200804 Pledgee: Guangzhou Caold financing Company limited by guarantee Pledgor: CHEN-STONE(GUANGZHOU) Co.,Ltd. Registration number: Y2022440000292 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |